



This is a repository copy of *A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose-ranging study of the efficacy and safety of Astodrimmer Gel for the treatment of bacterial vaginosis.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/163473/>

Version: Published Version

Article:

Waldbaum, A.S., Schwebke, J.R., Paull, J.R.A. et al. (5 more authors) (2020) A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose-ranging study of the efficacy and safety of Astodrimmer Gel for the treatment of bacterial vaginosis. PLoS ONE, 15 (5). e0232394. ISSN 1932-6203

<https://doi.org/10.1371/journal.pone.0232394>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:
<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>


RESEARCH ARTICLE

A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose-ranging study of the efficacy and safety of Astodrimmer Gel for the treatment of bacterial vaginosis

Arthur S. Waldbaum¹, Jane R. Schwebke², Jeremy R. A. Paull^{3*}, Clare F. Price³, Stephanie R. Edmondson³, Alex Castellarnau³, Philip McCloud⁴, George R. Kinghorn⁵

1 Downtown Women's Health Care, Denver, CO, United States of America, **2** Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, United States of America, **3** Starpharma Pty Ltd, Melbourne, VIC, Australia, **4** McCloud Consulting Group, Sydney, NSW, Australia, **5** Royal Hallamshire and Sheffield Teaching Hospitals, Sheffield, United Kingdom

* jeremy.paull@starpharma.com



OPEN ACCESS

Citation: Waldbaum AS, Schwebke JR, Paull JRA, Price CF, Edmondson SR, Castellarnau A, et al. (2020) A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose-ranging study of the efficacy and safety of Astodrimmer Gel for the treatment of bacterial vaginosis. PLoS ONE 15(5): e0232394. <https://doi.org/10.1371/journal.pone.0232394>

Editor: Werner Mendling, GERMANY

Received: July 15, 2019

Accepted: February 14, 2020

Published: May 4, 2020

Copyright: © 2020 Waldbaum et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: The study was funded by Starpharma Pty Ltd. Starpharma Pty Ltd was responsible for the design, data collection and analysis, decision to publish, and preparation of the manuscript. The funder provided support in the form of research funding for this study to ASW. The funder provided support in the form of salaries for JRAP, SRE, CFP

Abstract

Background

Astodrimmer Gel contains a novel dendrimer intended to treat and prevent bacterial vaginosis. We assessed the efficacy and safety of Astodrimmer Gel for treatment of bacterial vaginosis.

Methods

132 women with bacterial vaginosis were randomized 1:1:1:1 to Astodrimmer 0.5% (N = 34), 1% (N = 33), or 3% (N = 32) Gel or hydroxyethyl cellulose placebo gel (N = 33) at a dose of 5 g vaginally once daily for 7 days at 6 centers in the United States. The primary endpoint was clinical cure (no bacterial vaginosis vaginal discharge and no more than one of 1) vaginal pH ≥ 4.5 ; 2) $\geq 20\%$ clue cells; or 3) positive whiff test) at study days 21–30. Secondary analyses included clinical cure at study days 9–12, patient-reported symptoms, acceptability and adverse events.

Results

The Astodrimmer 1% Gel dose was superior to placebo for the primary and selected secondary efficacy measures in the modified intent-to-treat population. Clinical cure rates at day 9–12 were superior to placebo for the Astodrimmer 3%, 1% and 0.5% Gel groups (62.5% [15/24; $P = .002$], 74.1% [20/27; $P < .001$], and 55.2% [16/29; $P = .001$], respectively, vs. 22.2% [6/27]). At day 21–30, clinical cure rates were 46.2% (12/26) for the 1% dose vs. 11.5% for placebo (3/26; $P = .006$). A greater proportion of patients reported absence of vaginal discharge and vaginal odor at day 9–12 and day 21–30 for Astodrimmer Gel groups compared with placebo. Adverse events considered potentially treatment-related occurred in only 25% of Astodrimmer Gel-treated patients vs. 22% of placebo patients.

and AC, and consulting fees for JRS, PMcC and GRK. The specific roles of these authors are articulated in the 'author contributions' section.

Competing interests: Starpharma is the developer of Astodrimmer Gel, which has been licensed to and is now marketed by Aspen Pharmacare in Australia and New Zealand, and by Mundipharma in Europe and Asia. ASW received research funding from Gage Development Company. JRS is a paid consultant for Starpharma Pty Ltd, Talis One, Toltec, Lupin Pharmaceuticals, and Hologic. JRAP and SRE are paid employees of Starpharma Pty Ltd. CFP and AC were paid employees of Starpharma Pty Ltd and are now paid consultants for Starpharma Pty Ltd. PMcC and GRK are paid consultants for Starpharma Pty Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Conclusion

Astodrimmer Gel once daily for 7 days was superior to placebo for treatment of bacterial vaginosis and was well-tolerated. The 1% dose consistently showed the strongest efficacy across endpoints. These results support a role for Astodrimmer Gel, 1%, as an effective treatment for bacterial vaginosis.

Introduction

Bacterial vaginosis (BV) is the most common vaginal infection worldwide and is approximately twice as common as vulvovaginal candidiasis [1]. BV is associated with serious health consequences, including pre-term birth, and acquisition and transmission of human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs) [2] [3].

Most common treatments for BV are oral or vaginal antimicrobial drugs [4] [5]. Antibiotics, including various 5-nitroimidazole derivatives, metronidazole, tinidazole and secnidazole, and clindamycin are associated with high rates of candidiasis when used for treatment of BV [6] and are not well-tolerated by patients due to gastrointestinal side effects or interaction with alcohol. Current treatment options for BV are inadequate and alternate therapies are required [7] [8] [9].

Astodrimmer is of the class of novel compounds called dendrimers, characterized by a highly branched, three-dimensional architecture. Astodrimmer is a generation-four lysine dendrimer with a polyanionic surface charge [10]. Both size and surface charge of the dendrimer contribute to the function of the compound [11]. Astodrimmer is formulated in an aqueous, Carbo-pol[®]-based, muco-adhesive gel. Astodrimmer has been shown to inhibit growth of bacteria associated with BV via a novel mechanism of action compared with conventional antibiotics, by blocking the attachment of bacteria to cells and inhibiting the formation of and disrupting biofilms. Bacterial biofilms are important in the pathogenesis of BV and are not adequately targeted by existing therapies, leading to inadequate treatment and frequent recurrence [9] [12] [13] [14]. Astodrimmer is well-tolerated and not systemically absorbed [15] [16].

Therefore, Astodrimmer Gel offers the potential to be a non-antibiotic alternative that avoids issues associated with antibiotics. The current study assessed different doses of Astodrimmer Gel for treatment of women with BV.

Materials and methods

Study design

This was a double-blind, multicenter, randomized, placebo-controlled, dose-ranging study assessing the efficacy and safety of three strengths (0.5%, 1%, and 3%) of Astodrimmer Gel applied vaginally for 7 days compared with placebo (hydroxyethyl cellulose placebo gel) [17] [18] in women with BV.

The study complied with the Declaration of Helsinki, was conducted in accordance with Good Clinical Practice, regulatory guidelines, and relevant local legislation, and was approved by an institutional review board on July 23, 2010 (Quorum Review, Inc.). Patient enrolment commenced August 23, 2010 and last follow up was on February 25, 2011. The study was registered on clinicaltrials.gov on 12 September 2010 as NCT01201057. Registration was delayed with respect to first patient enrolled in line with US regulatory standards, which required registration within 21 days of the first patient being enrolled. The authors confirm that all ongoing and related trials for this product are registered.

All patients provided written informed consent and were screened for eligibility at the baseline visit (study day 1). Eligible patients were randomized in a 1:1:1:1 ratio to receive 0.5%, 1% or 3% Astodrimmer Gel or placebo gel using a computer-generated randomization list based upon a permutation block procedure. The three active gels and placebo were colorless gels packaged in identical, pre-filled, vaginal applicators. Each applicator contained a single-dose (5 g) and was individually overwrapped in a sealed pouch. Eight overwrapped applicators (7 doses and 1 spare) were packed in a tamper-evident carton labeled with a unique patient identification number (PIN). Each patient was assigned a PIN according to the randomization schedule and the corresponding carton was dispensed at baseline. Women self-administered a dose vaginally once a day for 7 days and then attended an end of treatment (EOT) visit between study days 9-12 for response assessments and evaluation of adverse events (AEs). A 2-3 week follow-up period concluded with a test of cure (TOC) visit between study days 21-30. Both care providers and patients were unaware of treatment allocations throughout the study. Patients could withdraw from the study at any time.

Women who reported no improvement in BV symptoms or who relapsed could request rescue therapy, provided the investigator confirmed the presence of BV. Women who received rescue medication were considered failures for clinical cure but were assessed for safety up to the final study visit.

The 3 gel strengths were chosen based on microbiology data. The 0.5% strength was chosen as data indicated efficacy against *Gardnerella vaginalis* without affecting *Lactobacillus* species (spp). The 3% strength was chosen as it provided the broadest activity against *Bacteroides ovatus*, *P. bivia* and *G. vaginalis*, and the 1% strength was selected to investigate a mid-range dose.

Study population

Women aged 18-45 years with a diagnosis of BV, defined as presence of 4 Amsel criteria for BV (discharge; vaginal fluid pH ≥ 4.5 ; $\geq 20\%$ clue cells; and positive 10% potassium hydroxide whiff test) [19] and Nugent score (NS) ≥ 4 [20] were randomized. The protocol allowed enrolment before confirmation of a NS ≥ 4 if an OSOM[®] BVBlue[®] test (Sekisui Diagnostics; Burlington MA, USA) returned a positive result.

Women who were pregnant, planning to become pregnant, lactating, or who were not willing to use contraception during the study, and women testing positive for urinary tract infection (UTI), or *Chlamydia trachomatis*, *Neisseria gonorrhoeae* or *Trichomonas vaginalis* infections at screening were excluded. Patients who had received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days of enrolment were excluded from the study.

Concomitant systemic and topical antimicrobial therapies and vaginal antifungal therapies were not permitted during the study, and the use of other vaginally administered products and oral antifungals was discouraged.

Outcomes

The primary efficacy endpoint was clinical cure defined as normal physiological discharge, and meeting no more than one other of 1) vaginal pH ≥ 4.5 ; 2) $\geq 20\%$ clue cells; or 3) positive whiff test at day 21-30. Clinical cure was also assessed at day 9-12, constituting a secondary efficacy endpoint. At the time of study conduct, the US Food and Drug Administration (FDA) required the assessment at study day 21-30 be the primary endpoint (FDA Guidance for Industry, titled *Bacterial Vaginosis; Developing Antimicrobial Drugs for Treatment*, issued July 22, 1998, withdrawn August 7, 2013). In 2016, FDA re-issued its guidance on BV (FDA Guidance for Industry, titled *Bacterial Vaginosis; Developing Antimicrobial Drugs for Treatment*, issued July 13, 2016), recommending the primary assessment of cure be at study day 7-14.

This timing is consistent with study days 7–10 for assessment of treatment success proposed by a US National Institutes of Health (NIH) workshop on BV clinical practice [5], and with the assessment at days 9–12 used in the current study. Other secondary endpoints assessed at study days 9–12 and 21–30 were Nugent cure (NS ≤ 3 when a score of ≥ 7 was determined at baseline); therapeutic cure, a composite of clinical cure and Nugent cure; and therapeutic resolution of BV, defined as clinical cure and NS < 6 .

Additional efficacy measures included resolution of each individual Amsel criteria; NS; use of rescue medication; presence of BV symptoms as assessed by the investigator and the patient; acceptability of study treatment from the Treatment Satisfaction Questionnaire for Medication (TSQM, Version 1.4) at day 9–12; and semi-quantitative culture analysis of vaginal flora.

AEs were monitored throughout the study.

Statistical analyses

A formal interim analysis was conducted after completion of the TOC visit for 50% of the participants. Data displays were produced by an independent statistician and programmer who were not part of the project team. An O'Brien-Fleming α -spending function was used for the interim analysis. No changes to the study were made on the basis of the interim analysis. The significance calculated for the final analysis was $\alpha = .048$.

Primary and secondary efficacy analyses using the Cochran-Mantel-Haenszel (CMH) test controlling for study center were performed on the modified Intent-To-Treat (mITT) population, which was all patients randomized who had administered ≥ 1 dose of study product, NS ≥ 4 at baseline, a post-baseline assessment of efficacy (NS or Amsel criteria) and non-use of prohibited medications that may have confounded efficacy assessment.

The safety population was all patients randomized who had received ≥ 1 dose of study product. The microbiological population was a subset of the ITT population and included patients that had at least one sample collected for semi-quantitative culture analysis of vaginal microflora.

Continuous efficacy variables (e.g., questionnaires or NS) were compared between all treatment groups using analysis of variance (ANOVA) adjusting for study center. The semi-quantitative culture analysis of vaginal microflora was presented descriptively.

Sample size calculation

Assuming clinical cure rates of 50% and 15% for Astodrimmer Gel and placebo, respectively, a sample size of 28 evaluable patients per treatment arm provided 80% power to detect a treatment difference with a final alpha significance level of $\alpha = .048$. Assuming a 15% attrition rate, 33 patients per treatment arm and 132 patients overall were to be randomized.

Results

Disposition and demographics

A total of 132 eligible women were randomized to receive placebo (N = 33), astodrimmer 3% (N = 32), astodrimmer 1% (N = 33) or astodrimmer 0.5% (N = 34) at 6 sites in the US. The mITT population included 111 women. Treatment groups were well-balanced with respect to demographic and baseline characteristics (Table 1). As presented in Fig 1, the majority of patients in all treatment groups completed treatment (at least 6 days) and the study.

Efficacy

Each of the astodrimmer groups was superior to placebo for clinical cure at day 9–12 (statistically significant), with the highest cure rate in the 1% astodrimmer group: 74.1% (20/27) vs. 22.2% (6/

Table 1. Baseline characteristics (mITT population), by treatment group.

	Astodrimmer Gel			Placebo
	3% (N = 26)	1% (N = 27)	0.5% (N = 30)	(N = 28)
Age (yr)				
Mean (SD)	29.5 (7.24)	30.0 (6.66)	29.0 (7.68)	30.6 (7.66)
Range	19 to 44	18 to 42	18 to 45	18 to 44
Race, n (%)				
White	12 (46.2%)	17 (63.0%)	19 (63.3%)	14 (50.0%)
Black	14 (53.8%)	10 (37.0%)	9 (30.0%)	11 (39.3%)
All Others ^a	0	0	2 (6.7%)	3 (10.7%)
Ethnicity, n (%)				
Non-Hispanic	20 (76.9%)	20 (74.1%)	22 (73.3%)	22 (78.6%)
Hispanic	6 (23.1%)	7 (25.9%)	8 (26.7%)	6 (21.4%)
Nugent score, n (%)				
4 to 6	5 (19.2%)	3 (11.1%)	8 (26.7%)	3 (10.7%)
7 to 10	21 (80.8%)	24 (88.9%)	22 (73.3%)	25 (89.3%)

N = number of patients analyzed, n = number of patients with observation, mITT = modified intent-to-treat, SD = standard deviation

^a All Others = Asian, Native American

<https://doi.org/10.1371/journal.pone.0232394.t001>

27) in placebo ($P < .001$) (Table 2). At day 21–30, the primary outcome measure of clinical cure rate for the 1% astodrimmer group was statistically significantly higher than placebo: 46.2% (12/26) vs. 11.5% (3/26), respectively ($P = .006$).

The clinical and Nugent cure results were supported by therapeutic cure and therapeutic resolution data, where a greater proportion of patients in the astodrimmer groups (compared with placebo) met the criteria (Table 2).

Significantly more patients treated with astodrimmer experienced resolution of each individual Amsel criteria compared to those treated with placebo. Abnormal discharge resolved from baseline to day 9–12 for 88.9% of patients in the 1% astodrimmer group compared to 35.7% of placebo patients ($P < .001$), positive whiff test resolved for 74.1% vs. 25.0% ($P < .001$), pH resolved for 33.3% vs. 7.1% ($P = .006$) and clue cells resolved for 88.9% vs. 25.0% ($P < .001$) (Fig 2). At day 21–30, a similar pattern was observed (Fig 3).

At baseline, most patients in all treatment groups had a NS categorized as 'BV'. At day 9–12, the NS was categorized as 'normal' for 7.4% of placebo-treated patients compared to 28.0%, 26.9% and 27.6% of patients who were treated with astodrimmer (3%, 1% and 0.5% doses, respectively, $P < .001$). Whilst most placebo-treated patients remained categorized as 'BV' at day 9–12 (88.9%), fewer than one-third of astodrimmer-treated patients remained 'BV', regardless of dose (28.8%, 23/83; $P < .001$). Similar results were observed at day 21–30, although differences between the astodrimmer and placebo groups were not statistically significant.

Both the investigator and patient symptom questionnaire responses supported the other efficacy findings. At day 9–12 and day 21–30, there were more patients who reported absence of symptoms of discharge and odor in the astodrimmer groups (most notably the 1% dose) compared to placebo. At day 9–12, 63.0% and 77.8% of women given 1% astodrimmer reported absence of vaginal discharge and absence of vaginal odor, respectively, compared to 25.0% and 28.6%, respectively, for placebo. Most women in the astodrimmer groups also reported absence of discharge and odor at day 21–30. For the 1% dose group at day 21–30, 63.0% and 59.3% had absence of discharge and odor, respectively, compared with 25.0% and 25.0%, for placebo.




Fig 1. Consort diagram. Patient enrollment by treatment group.

<https://doi.org/10.1371/journal.pone.0232394.g001>

Time to first absence of discharge, odor, and discharge and odor was somewhat shorter in the astodrimmer groups compared with placebo. When considering only responders (i.e., meeting requirements for clinical cure at day 21–30) the median [95% confidence interval {CI}] times to first resolution were: i) vaginal odor: 1 [0, 6] day for the 1% dose compared with 7 [0, 19] days for placebo; ii) vaginal discharge: 4 [2, 8] days for the 1% dose compared with 9 [0, 21] days for placebo; and iii) vaginal discharge and odor: 5.5 [2, 11] days for the 1% dose compared with 9 [0, 21] days for placebo.

Rescue medication (typically oral metronidazole or tinidazole) was needed by fewer women who received 3%, 1% and 0.5% astodrimmer (50.0%, 25.9%, and 56.7%, respectively) than those who received placebo (75.0%). In the astodrimmer groups, of those patients who received rescue medication, most did so at the day 21–30 visit. For placebo, uptake of rescue medication was similar at the day 9–12 visit, the day 21–30 visit, and between the two visits.

Table 2. Efficacy outcomes (mITT population), by treatment group.

	Astodrimmer Gel			Placebo
	3%	1%	0.5%	
	n/N (%)	n/N (%)	n/N (%)	n/N (%)
	[95% CI]	[95% CI]	[95% CI]	[95% CI]
	<i>P</i> -value ^a	<i>P</i> -value ^a	<i>P</i> -value ^a	
Clinical Cure				
Day 9–12	15/24 (62.5)	20/27 (74.1)	16/29 (55.2)	6/27 (22.2)
	[40.6, 81.2]	[53.7, 88.9]	[35.7, 73.6]	[8.6, 42.3]
	<i>P</i> = .002	<i>P</i> < .001	<i>P</i> = .010	
Day 21–30	7/25 (28.0)	12/26 (46.2)	7/30 (23.3)	3/26 (11.5)
	[12.1, 49.4]	[26.6, 66.6]	[9.9, 42.3]	[2.4, 30.2]
	<i>P</i> = .158	<i>P</i> = .006	<i>P</i> = .248	
Nugent Cure				
Day 9–12	6/25 (24.0)	5/26 (19.2)	6/29 (20.7)	0/27 (0)
	[9.4, 45.1]	[6.6, 39.4]	[8.0, 39.7]	[0.0, 12.8]
	<i>P</i> = .006	<i>P</i> = .025	<i>P</i> = .015	
Day 21–30	3/25 (12.0)	5/26 (19.2)	3/30 (10.0)	1/26 (3.8)
	[2.5, 31.2]	[6.6, 39.4]	[2.1, 26.5]	[0.1, 19.6]
	<i>P</i> = .361	<i>P</i> = .069	<i>P</i> = .412	
Therapeutic Cure				
Day 9–12	2/24 (8.3)	7/26 (26.9)	5/29 (17.2)	2/27 (7.4)
	[1.0, 27.0]	[11.6, 47.8]	[5.8, 35.8]	[0.9, 24.3]
	<i>P</i> > .500	<i>P</i> = .073	<i>P</i> = .219	
Day 21–30	4/25 (16.0)	5/26 (19.2)	3/30 (10.0)	2/26 (7.7)
	[4.5, 36.1]	[6.6, 39.4]	[2.1, 26.5]	[0.9, 25.1]
	<i>P</i> = .493	<i>P</i> = .247	<i>P</i> > .500	
Therapeutic Resolution				
Day 9–12	13/24 (54.2)	13/26 (50.0)	11/29 (37.9)	3/27 (11.1)
	[32.8, 74.4]	[29.9, 70.1]	[20.7, 57.7]	[2.4, 29.2]
	<i>P</i> = .001	<i>P</i> = .006	<i>P</i> = .018	
Day 21–30	5/25 (20.0)	9/26 (34.6)	3/30 (10.0)	3/26 (11.5)
	[6.8, 40.7]	[17.2, 55.7]	[2.1, 26.5]	[2.4, 30.2]
	<i>P</i> = .491	<i>P</i> = .062	<i>P</i> > .500	

CI = confidence interval, N = number of patients analyzed, n = number of patients with observation

^a Pairwise *P*-value comparing each astodrimmer gel strength to placebo

Similarly, a greater proportion of patients in each of the astodrimmer groups compared with placebo met the criteria for Nugent cure at day 9–12 (statistically significant for each group) and day 21–30 (*P* = .069 for 1% astodrimmer group).

<https://doi.org/10.1371/journal.pone.0232394.t002>

Acceptability

The TSQM results supported other efficacy findings. At day 9–12, mean scores were greater for women receiving 3%, 1% and 0.5% astodrimmer compared to placebo for effectiveness (68.6 [*P* < .001], 69.1 [*P* < .001] and 60.4 [*P* = .017], respectively, vs. 45.5 placebo) and Global Satisfaction (69.5 [*P* = .002], 75.0 [*P* < .001] and 61.2 [*P* = .042], respectively, vs. 46.6 placebo). The highest scores were observed for the 1% astodrimmer group. Scores for convenience and tolerability were comparable between the astodrimmer and placebo groups.




Fig 2. Resolution of Amsel criteria at day 9–12. Resolution of individual Amsel criteria (discharge, whiff test, clue cells and pH >4.5) at day 9–12, by treatment group (astodrimmer 1%: N = 27; placebo: N = 28) (mITT population).

<https://doi.org/10.1371/journal.pone.0232394.g002>

Vaginal microflora culture analysis

The number of patients with *G. vaginalis*-positive cultures was reduced by more than half at day 9–12 compared to baseline in each of the astodrimmer groups (e.g., from 87.9% [29/33] to 42.4% [14/33] in the 1% dose group). The reduction in the placebo group was modest: from 87.9% (29/33) to 72.7% (24/33). The number of women with *G. vaginalis* growth at day 21–30 remained lower than at baseline in all treatment groups. Anaerobic Gram-negative rods (pigmented and non-pigmented) were also reduced by treatment with astodrimmer, with greater decreases compared to placebo for all astodrimmer groups at day 9–12. The treatment appeared benign with respect to changes in *Lactobacillus* spp. There was no increase, and in fact a minor




Fig 3. Resolution of Amsel criteria at day 21–30. Resolution of individual Amsel criteria (discharge, whiff test, clue cells and pH >4.5) at day 21–30, by treatment group (astodrimmer 1%: N = 27; placebo: N = 28) (mITT population).

<https://doi.org/10.1371/journal.pone.0232394.g003>

Table 3. Tolerability by treatment group (safety population).

Parameter	3% Astodrimmer N = 29 n (%)	1% Astodrimmer N = 32 n (%)	0.5% Astodrimmer N = 32 n (%)	Any Astodrimmer N = 93 n (%)	Placebo N = 32 n (%)
Patients with ≥ 1 AE	20 (69.0)	19 (59.4)	22 (68.8)	61 (65.6)	23 (71.9)
Patients with ≥ 1 AE considered by investigator to be potentially related to study treatment	9 (31.0)	6 (18.8)	8 (25.0)	23 (24.7)	7 (21.9)
Patients with ≥ 1 severe AE	0	0	0	0	2 (6.3)
Patients with ≥ 1 serious AE	0	0	0	0	0
Patients with ≥ 1 GUAE considered by investigator to be potentially related to study treatment	7 (24.1)	6 (18.8)	8 (25.0)	21 (22.6)	7 (21.9)
Patients who stopped treatment due to AE	1 (3.4)	1 (3.1)	0	2 (2.2)	0
AE of special interest					
Vulvovaginal candidiasis/mycotic infection	3 (10.3)	2 (6.3)	2 (6.3)	7 (7.5)	1 (3.1)
Urinary Tract Infection/Cystitis	0	1 (3.1)	0	1 (1.1)	2 (6.3)
Metrorrhagia	0	0	2 (6.3)	2 (2.2)	0
Vulvovaginal erythema	0	1 (3.1)	0	1 (1.1)	0
Vulvovaginitis	1 (3.4)	2 (6.3)	1 (3.1)	4 (4.3)	1 (3.1)
AEs considered by investigator to be potentially related to study treatment (incidence $\geq 5\%$)					
Vulvovaginal pruritus	2 (6.9)	2 (6.3)	4 (12.5)	8 (8.6)	4 (12.5)
Vulvovaginal burning sensation	2 (6.9)	2 (6.3)	1 (3.1)	5 (5.4)	0
Vulvovaginal candidiasis/mycotic infection	3 (10.3)	1 (3.1)	1 (3.1)	5 (5.4)	1 (3.1)
Metrorrhagia	0	0	2 (6.3)	2 (2.2)	0

AE = adverse event, GUAE = genitourinary adverse event, N = number of patients analyzed, n = number of patients with observation

<https://doi.org/10.1371/journal.pone.0232394.t003>

decrease, in the number of women culture positive for *Candida* spp. at day 9–12 and day 21–30 compared with baseline.

Safety/tolerability

The overall incidence of AEs was 71.9% (23/32) for placebo vs. 65.6% (61/93) for the astodrimmer groups (Table 3). During the treatment phase, AE incidences were 56.2% (18/32) and 51.6% (48/93) for women administered placebo and astodrimmer, respectively. During follow-up, these incidences were 50.0% (16/32) and 41.9% (39/93), respectively. AE incidence in patients administered 1% astodrimmer was the lowest among the groups.

Incidence of AEs potentially related to study treatment was 24.7% (23/93) for the astodrimmer groups vs. 21.9% (7/32) for placebo. Patients administered 1% astodrimmer had an AE incidence of 18.8% (6/32), the lowest among the treatment groups. Genitourinary AEs (GUAEs) potentially related to treatment were reported in women administered astodrimmer (22.6% [21/93]) at a similar rate to those given placebo (21.9%, [7/32]).

Just 1 patient (3.1%) in the 1% dose group and 1 patient (3.1%) in the placebo group experienced non-GUAEs potentially related to treatment (lethargy and headache, respectively). AEs of special interest (candidiasis [or vulvovaginal mycotic infection]), UTI [or cystitis], metrorrhagia, vulvovaginitis and vulvovaginal erythema) were infrequent. The rate of vulvovaginal candidiasis considered by the investigator to be potentially related to study treatment in the 1% astodrimmer group was 3.1% (1/32) and 3.1% (1/32) for placebo.

Most AEs were mild or moderate in intensity. Severe AEs were only reported for 2 women, both of whom were placebo-treated. There were 2 AEs leading to treatment discontinuation; dysmenorrhea in the 3% astodrimmer group, and sinusitis in the 1% astodrimmer group; neither was considered related to study treatment. There were no serious AEs (SAEs).

Discussion

Astodrimer is a new agent from the class of compounds called dendrimers. Astodrimer features a large molecular size and negative charge, which prevent systemic absorption and interfere with the ability of bacteria to adhere to surfaces inhibiting formation of and disrupting biofilms. A new therapy for the treatment of BV that avoids issues of conventional antibiotics, such as systemic exposure, candidiasis and antibiotic resistance, and has a novel mechanism of action targeting biofilms, offers a promising potential treatment modality for BV.

In this study, the clinical cure rate for 1% astodrimer at day 9–12 (74.1%) compares favorably to cure rates reported for conventional antibiotic products such as oral secnidazole (57.9%) [21] and metronidazole 1.3% gel (46%) [22] using comparable cure criteria assessed at a similar timeframe. The cure rate also compares favorably with BV cure rates obtained with an experimental boric acid/ethylenediamine tetra acetic acid (EDTA) vaginal gel intended to target biofilm in BV (50%) [23].

The median time to resolution of vaginal odor after starting treatment with Astodrimer Gel was 1 day. This result also compares favorably with a median time to resolution of vaginal odor for metronidazole gel, 1.3% and 0.75%, of 2 and 3 days, respectively, suggesting a more rapid relief of the highly problematic symptom of vaginal odor for Astodrimer Gel, 1%, compared with conventional antibiotics [24]. The findings of rapid and maintained symptom resolution are important in the context of the clinical management of BV, which is driven by presence and resolution of symptoms.

Differences between the astodrimer groups and placebo narrowed at the day 21–30 visit but clinical cure, the primary endpoint of the study, remained statistically significantly higher in the 1% astodrimer group compared with placebo. The clinical cure rate of 46.2% at day 21–30 is comparable to oral secnidazole using comparable cure criteria at a similar timeframe [21], and compares favorably with a study of metronidazole 0.75% gel showing that the clinical cure rate at day 21–30 was 28.8% [24].

Despite the narrowing of differences, there was a lower use of rescue medication by women receiving astodrimer in this study, and the non-antibiotic mechanism and well tolerated safety profile of Astodrimer Gel means that the product may be better-suited than standard antibiotic therapies for repeat courses, and for longer-term maintenance or preventive therapy in cases where that is required [25].

The safety profile of astodrimer was reflective of a topically applied, non-systemically absorbed product. No severe AEs were reported for astodrimer treated patients. Two AEs led to treatment discontinuation but neither case was considered treatment related.

Notably, the incidence of candidiasis for Astodrimer Gel, 1%, (6.3%, 2/32) was less than half that reported for secnidazole (13.6%, 17/125) [21].

Astodrimer was associated with positive changes in vaginal microflora as assessed by semi-quantitative culture analysis. Culture and identification of bacteria from vaginal specimens is challenging, so the results of this aspect should be interpreted with caution [26]. Overall, however, the changes in astodrimer groups appeared to be associated with BV cure and improved symptoms, while potentially related AEs, such as candidiasis and UTI, were reported infrequently.

That the 1% dose achieved the best results in this study was somewhat surprising but is consistent with the hypothesis that the treatment of BV with astodrimer restores the vaginal flora to a more normal balance; therefore, a lower dose could fail to exert enough antimicrobial activity, while a higher dose could have an inhibitory effect in certain beneficial bacterial species, such as lactobacilli. This effect has been observed with another topically applied therapy, rifaximin, where a mid-range dose achieved highest rates of cure of BV [27].

Strengths and limitations

Strengths of the study are that it was double-blind, multicenter, placebo controlled, and randomized. The study was adequately powered to detect a difference in BV cure rates between astodrimer and placebo.

A limitation of the study design was that randomization was not stratified for study center, since some assessments were investigator based, nor for women's prior BV history, since number of prior episodes may represent a prognostic factor in the resolution of BV.

Conclusions

Astodrimer Gel once daily for 7 days was superior to placebo for treatment of BV, was well-tolerated, and provided rapid resolution of BV symptoms. Patients found the treatment convenient and tolerable, and superior to placebo with respect to overall satisfaction and perceived efficacy. Clinical cure rates were generally favorable or comparable to those reported with conventional antibiotics.

These findings demonstrate the potential clinical utility of Astodrimer Gel, 1%, as an alternative treatment for BV with a novel mechanism of action related to disruption of biofilms. The product acts locally and is not systemically absorbed, offering patients and clinicians an additional safe treatment option that avoids potential issues associated with existing conventional antibiotics, such as high rates of candidiasis and antibiotic resistance. The 1% astodrimer dose consistently showed the strongest efficacy across primary and secondary endpoints, and was selected for assessment in phase 3 studies to confirm efficacy and safety findings [28].

Supporting information

S1 Checklist. CONSORT checklist.

(DOC)

S1 Dataset. Analysis populations.

(XLSX)

S2 Dataset. Efficacy outcomes.

(XLSX)

S3 Dataset. Symptom outcomes.

(XLSX)

S4 Dataset. Safety.

(XLSX)

S1 Data. Study protocol.

(PDF)

Acknowledgments

The authors would like to thank all the patients who were involved in the study and the Principal Investigators for involvement with the clinical trial. Editorial and medical writing assistance was provided by Angela Hart, MSc, of Quanticate UK Ltd.

Author Contributions

Conceptualization: Jeremy R. A. Paull, Clare F. Price, George R. Kinghorn.

Formal analysis: Philip McCloud.

Investigation: Arthur S. Waldbaum.

Methodology: George R. Kinghorn.

Project administration: Jeremy R. A. Paull, Clare F. Price, Stephanie R. Edmondson.

Resources: Jeremy R. A. Paull, Clare F. Price.

Supervision: Jeremy R. A. Paull, Clare F. Price.

Visualization: Jeremy R. A. Paull, Alex Castellarnau.

Writing – original draft: Alex Castellarnau.

Writing – review & editing: Arthur S. Waldbaum, Jane R. Schwebke, Jeremy R. A. Paull, Clare F. Price, Stephanie R. Edmondson, Alex Castellarnau, Philip McCloud, George R. Kinghorn.

References

1. Barbone F, Austin H, Louv WC, et al. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. *Am J Obstet Gynecol.* 1990; 163(2):510–14. [https://doi.org/10.1016/0002-9378\(90\)91186-g](https://doi.org/10.1016/0002-9378(90)91186-g) PMID: 2167008
2. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. *N Engl J Med.* 1995; 333:1737–42. <https://doi.org/10.1056/NEJM199512283332604> PMID: 7491137
3. Schwebke JR. New concepts in the etiology of bacterial vaginosis. *Current Infectious Disease Reports.* 2009; 11(2):143–7. <https://doi.org/10.1007/s11908-009-0021-7> PMID: 19239805
4. Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines. *MMWR.* 2015; 64(RR-03):1–137. PMC5885289. PMID: 26042815
5. Marrazzo JM, Martin DH, Watts DH, et al. Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. *Sex Transm Dis.* 2010 Dec; 37(12):732–44. <https://doi.org/10.1097/OLQ.0b013e3181fbbc95> PMID: 21068695
6. Ferris DG, Litaker MS, Woodward L, Mathis D, Hendrich J. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. *J Fam Pract.* 1995 Nov; 41(5):443–9. PMID: 7595261
7. Schwebke JR and Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. *Clin Infect Dis.* 2007; 44:213–19. <https://doi.org/10.1086/509577> PMID: 17173219
8. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. *J Infect Dis.* 2006; 193:1478–86. <https://doi.org/10.1086/503780> PMID: 16652274
9. Bradshaw CS and Sobel JD. Current treatment of bacterial vaginosis—Limitations and need for innovation. *J Infect Dis.* 2016; 214(Suppl 1):S14–20.
10. McCarthy TD, Karellas P, Henderson SA, et al. Dendrimers as Drugs: Discovery and Preclinical and Clinical Development of Dendrimer-Based Microbicides for HIV and STI Prevention. *Molecular Pharmaceutics* 2005; 2(4):312–18. <https://doi.org/10.1021/mp050023q> PMID: 16053334
11. Tyssen D, Henderson SA, Johnson A, et al. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. *PLoS One.* 2010 Aug 23; 5(8):e12309. <https://doi.org/10.1371/journal.pone.0012309> PMID: 20808791
12. Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. *Obstet. Gynecol.* 2005; 106(5 Pt 1):1013–23. <https://doi.org/10.1097/01.AOG.0000183594.45524.d2> PMID: 16260520
13. Muzny CA and Schwebke JR. Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections. *Clin Infect Dis* 2015; 61(4):601–6. <https://doi.org/10.1093/cid/civ353> PMID: 25935553
14. Machado D, Castro J, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, Cerca N. Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions. *Front Microbiol.* 2016; 6:1528. <https://doi.org/10.3389/fmicb.2015.01528> PMID: 26834706

15. O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, Paull JRA. Safety, tolerability, and Pharmacokinetics of SPL7013 Gel (VivaGel®): A dose–ranging, phase I study. *Sex Transm Dis.* 2010; 37(2):100–104. <https://doi.org/10.1097/OLQ.0b013e3181bc0aac> PMID: [19823111](https://pubmed.ncbi.nlm.nih.gov/19823111/)
16. McGowan I, Gomez K, Bruder K, et al and the MTN–004 Protocol Team. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 Gel (VivaGel®) in sexually active young women (MTN-004). *AIDS.* 2011 May 15; 25(8):1057–64. <https://doi.org/10.1097/QAD.0b013e328346bd3e> PMID: [21505316](https://pubmed.ncbi.nlm.nih.gov/21505316/)
17. Tien D, Schnaare RL, Kang F, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. *AIDS Res Hum Retroviruses.* 2005 Oct; 21(10):845–53. <https://doi.org/10.1089/aid.2005.21.845> PMID: [16225411](https://pubmed.ncbi.nlm.nih.gov/16225411/)
18. Schwartz JL, Ballagh SA, Kwok C, et al. Fourteen-day safety and acceptability study of the universal placebo gel. *Contraception.* 2007 Feb; 75(2):136–41. <https://doi.org/10.1016/j.contraception.2006.09.003> PMID: [17241844](https://pubmed.ncbi.nlm.nih.gov/17241844/)
19. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. *Am J Med.* 1983; 74:14–22. [https://doi.org/10.1016/0002-9343\(83\)91112-9](https://doi.org/10.1016/0002-9343(83)91112-9) PMID: [6600371](https://pubmed.ncbi.nlm.nih.gov/6600371/)
20. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. *J Clin Microbiol.* 1991; 29:297–301. PMID: [1706728](https://pubmed.ncbi.nlm.nih.gov/1706728/)
21. Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. *Am J Obstet Gynecol.* 2017; 217:678.e1–9.
22. Schwebke JR, Marrazzo J, Beelen AP, Sobel JD. A Phase 3, multicenter, randomized, double-blind, vehicle-controlled study evaluating the safety and efficacy of metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis. *Sex Transm Dis.* 2015; 42(7):376–381. <https://doi.org/10.1097/OLQ.0000000000000300> PMID: [26222750](https://pubmed.ncbi.nlm.nih.gov/26222750/)
23. Marrazzo J, Dombrowski JC, Wierzbicki MR, et al. Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: a randomized, single-blind, phase 2, controlled trial. *Clin Infect Dis.* 2019; 68:803–809. <https://doi.org/10.1093/cid/ciy554> PMID: [30184181](https://pubmed.ncbi.nlm.nih.gov/30184181/)
24. Chavoustie SE, Jacobs M, Reisman HA, et al. Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose–ranging study. *J Low Genit Tract Dis.* 2015 Apr; 19(2):129–34. <https://doi.org/10.1097/LGT.0000000000000062> PMID: [24983350](https://pubmed.ncbi.nlm.nih.gov/24983350/)
25. Schwebke J, Carter B, Waldbaum A, et al. Results of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of astodrimer gel for prevention of recurrent bacterial vaginosis. *Am J Obstet Gynecol.* 2019; 221(6):672–673.
26. Money D. The laboratory diagnosis of bacterial vaginosis. *Can J Infect Dis Med Microbiol.* 2005. Mar–Apr; 16(2): 77–79. <https://doi.org/10.1155/2005/230319> PMID: [18159532](https://pubmed.ncbi.nlm.nih.gov/18159532/)
27. Donders GG, Guaschino S, Peters K, Tacchi R, Lauro V; VARIANT 1 Study Group. A multicenter, double-blind, randomized, placebo-controlled study of rifaximin for the treatment of bacterial vaginosis. *Int J Gynaecol Obstet.* 2013 Feb; 120(2):131–6. <https://doi.org/10.1016/j.ijgo.2012.08.022> Epub 2012 Dec 27. PMID: [23273888](https://pubmed.ncbi.nlm.nih.gov/23273888/)
28. Chavoustie SE, Carter BA, Waldbaum AS, et al. Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis. *Eur J Obstet Gynecol Reprod Biol.* 2020; 245:13–18. <https://doi.org/10.1016/j.ejogrb.2019.11.032> PMID: [31812702](https://pubmed.ncbi.nlm.nih.gov/31812702/)